JP2016512199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512199A5 JP2016512199A5 JP2015561627A JP2015561627A JP2016512199A5 JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5 JP 2015561627 A JP2015561627 A JP 2015561627A JP 2015561627 A JP2015561627 A JP 2015561627A JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- pharmaceutical composition
- cell surface
- surface molecule
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 241000700562 Myxoma virus Species 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772803P | 2013-03-05 | 2013-03-05 | |
| US61/772,803 | 2013-03-05 | ||
| PCT/US2014/020935 WO2014138314A1 (en) | 2013-03-05 | 2014-03-05 | Oncolytic virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512199A JP2016512199A (ja) | 2016-04-25 |
| JP2016512199A5 true JP2016512199A5 (enExample) | 2017-04-06 |
Family
ID=50424733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561627A Pending JP2016512199A (ja) | 2013-03-05 | 2014-03-05 | 腫瘍溶解性ウイルス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160000842A1 (enExample) |
| EP (1) | EP2964241A1 (enExample) |
| JP (1) | JP2016512199A (enExample) |
| CN (1) | CN105407902A (enExample) |
| CA (1) | CA2903096A1 (enExample) |
| WO (1) | WO2014138314A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| SG11201602887QA (en) | 2013-10-25 | 2016-05-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
| EP3858991A1 (en) * | 2014-09-26 | 2021-08-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| AU2016232009B2 (en) | 2015-03-17 | 2021-07-15 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| SG11201708604TA (en) | 2015-04-30 | 2017-11-29 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
| WO2017013421A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| JP6920786B2 (ja) * | 2015-08-26 | 2021-08-18 | ドイチェス クレブスフォルシュンクスツェントルム | 免疫ウイルス療法のためのｒｎａウイルス |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| EA201891022A1 (ru) * | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| CN109983121A (zh) * | 2016-06-30 | 2019-07-05 | 昂克诺斯公司 | 治疗性多肽的假型化溶瘤病毒递送 |
| AU2017298385A1 (en) | 2016-07-19 | 2019-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting STAT3 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| MY197324A (en) * | 2016-08-29 | 2023-06-13 | Akamis Bio Ltd | Adenovirus armed with bispecific t cell activator |
| TW201825674A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| AU2017335673B2 (en) | 2016-09-27 | 2024-11-14 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| AU2018215558B2 (en) * | 2017-02-03 | 2023-05-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| IL270138B2 (en) * | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| CN107164338A (zh) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | 一种重组溶瘤病毒及其应用 |
| GB201721833D0 (en) * | 2017-12-22 | 2018-02-07 | Cancer Research Tech Ltd | Fusion proteins |
| TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對ｔｉｇｉｔ之單域抗體及其變異體 |
| EP3731850A4 (en) * | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| KR102839330B1 (ko) | 2018-01-15 | 2025-07-30 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| CA3094235A1 (en) * | 2018-04-13 | 2019-10-17 | F. Hoffmann-La Roche Ag | Her2-targeting antigen binding molecules comprising 4-1bbl |
| WO2019226617A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| EP3823668A1 (en) | 2018-07-16 | 2021-05-26 | DCPrime B.V. | A combination product for use in tumor vaccination |
| US20220370527A1 (en) * | 2018-07-20 | 2022-11-24 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| WO2020217226A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
| CA3139643A1 (en) * | 2019-06-27 | 2020-12-30 | Bionoxx Inc. | Oncolytic virus with improved safety and anticancer effects |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| EP3957650A1 (en) * | 2020-08-17 | 2022-02-23 | Themis Bioscience GmbH | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| AU2022211682A1 (en) | 2021-01-22 | 2023-08-03 | Mendus B.V. | Methods of tumor vaccination |
| CN115161293B (zh) * | 2021-04-01 | 2024-11-15 | 南京惟亚德生物医药有限公司 | 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用 |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| JP2009521474A (ja) * | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| JP6420776B2 (ja) * | 2013-03-05 | 2018-11-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫療法のためのエンゲージャー細胞 |
-
2014
- 2014-03-05 CN CN201480025597.3A patent/CN105407902A/zh active Pending
- 2014-03-05 CA CA2903096A patent/CA2903096A1/en not_active Abandoned
- 2014-03-05 US US14/770,061 patent/US20160000842A1/en not_active Abandoned
- 2014-03-05 EP EP14714851.4A patent/EP2964241A1/en not_active Ceased
- 2014-03-05 JP JP2015561627A patent/JP2016512199A/ja active Pending
- 2014-03-05 WO PCT/US2014/020935 patent/WO2014138314A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514956A5 (enExample) | ||
| Fang et al. | NK cell-based immunotherapy for cancer | |
| JP2019519245A5 (enExample) | ||
| Pol et al. | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors | |
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| WO2019236633A3 (en) | Cell-based vehicles for potentiation of viral therapy | |
| JP2017029157A5 (enExample) | ||
| RU2019102391A (ru) | Доставка терапевтических полипептидов посредством псевдотипированных онкологических вирусов | |
| JP2018512047A5 (enExample) | ||
| JP2019513118A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2018527952A5 (enExample) | ||
| JP2019536806A5 (enExample) | ||
| Chulpanova et al. | Recombinant viruses for cancer therapy | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| JP2008056679A5 (enExample) | ||
| JP2016531927A5 (enExample) | ||
| EP3812401A1 (en) | Chimeric antigen receptor comprising third signal receptor and use thereof | |
| PH12016500859B1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| JP2014532649A5 (enExample) | ||
| JP2018535668A5 (enExample) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |